Technical Analysis for GDTC - CytoMed Therapeutics Limited
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New Downtrend | Bearish | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Inside Day | Range Contraction | -1.29% | |
| Gapped Up | Strength | -1.29% | |
| Down 3 Days in a Row | Weakness | -1.29% | |
| Oversold Stochastic | Weakness | -1.29% | |
| Stochastic Buy Signal | Bullish | -2.01% | |
| Volume Surge | Other | -2.01% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | 1 day ago |
| Down 3% | 1 day ago |
| Down 2 % | 1 day ago |
| Down 1% | 1 day ago |
| Possible NR7 | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 11/29/2023
CytoMed Therapeutics Limited Description
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore. CytoMed Therapeutics Limited operates as a subsidiary of Glorious Finance Ltd
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Immune System Immunotherapy Cancer Treatment Immunotherapies Virotherapy Chimeric Antigen Receptor T Cell Natural Killer Cell Lymphocytes T Cells Human Cancers Pre Clinical Biopharmaceutical
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.25 |
| 52 Week Low | 2.36 |
| Average Volume | 5,732 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 3.67 |
| 20-Day Moving Average | 3.72 |
| 10-Day Moving Average | 3.57 |
| Average True Range | 0.17 |
| RSI (14) | 36.31 |
| ADX | 25.63 |
| +DI | 11.22 |
| -DI | 30.98 |
| Chandelier Exit (Long, 3 ATRs) | 3.76 |
| Chandelier Exit (Short, 3 ATRs) | 3.85 |
| Upper Bollinger Bands | 4.13 |
| Lower Bollinger Band | 3.31 |
| Percent B (%b) | 0.12 |
| BandWidth | 21.94 |
| MACD Line | -0.08 |
| MACD Signal Line | -0.04 |
| MACD Histogram | -0.0429 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.66 | ||||
| Resistance 3 (R3) | 3.67 | 3.58 | 3.62 | ||
| Resistance 2 (R2) | 3.58 | 3.52 | 3.58 | 3.61 | |
| Resistance 1 (R1) | 3.50 | 3.48 | 3.45 | 3.49 | 3.59 |
| Pivot Point | 3.41 | 3.41 | 3.39 | 3.41 | 3.41 |
| Support 1 (S1) | 3.33 | 3.35 | 3.29 | 3.33 | 3.23 |
| Support 2 (S2) | 3.24 | 3.31 | 3.24 | 3.21 | |
| Support 3 (S3) | 3.16 | 3.24 | 3.20 | ||
| Support 4 (S4) | 3.16 |
